Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. The company was founded in 1999 and is headquartered in Paris, France.
IPO Year: 2015
Exchange: NASDAQ
Website: cellectis.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/17/2023 | $6.00 | Buy | Bryan Garnier |
| 5/18/2022 | $10.00 | Neutral → Outperform | Robert W. Baird |
| 1/6/2022 | $16.00 | Overweight → Equal-Weight | Wells Fargo |
| 11/30/2021 | $20.00 | Mkt Outperform | JMP Securities |
| 11/8/2021 | Outperform → Mkt Perform | William Blair | |
| 10/8/2021 | $39.00 → $10.00 | Outperform → Neutral | Baird |
| 10/8/2021 | $39.00 → $10.00 | Outperform → Neutral | Robert W. Baird |